Navigation Links
New Nationwide Study on Leading Cause of Vision Loss for Seniors

UT Southwestern Medical Center is participating in a nationwide study investigating //whether modified combinations of vitamins, minerals and fish oil products can slow the progression of vision loss from age-related macular degeneration.

“This study will evaluate nutrient-based factors that may influence the development and progression of the two most prevalent age-related eye diseases, age-related macular degeneration and cataracts,” said Dr. Yu-Guang He, an ophthalmologist and principal investigator of the study at UT Southwestern.

The Age-Related Eye Disease Study 2, sponsored by the National Institutes of Health, will build upon results from an earlier study that found high-dose antioxidant vitamins and minerals taken orally reduced the risk of AMD progression by 25 percent and the risk of moderate vision loss by 19 percent. That study involved vitamins C and E, beta carotene, zinc and copper.

The new study will examine whether adding lutein and zeaxanthin (derived from plants) and omega-3 fatty acids DHA and EPA (derived from fish oil) decreases progression to advanced AMD, which often leads to vision loss. It will also consider the effect these supplements have on cataract and moderate vision loss.

“Everybody talks about the potential benefit of these supplements, but there’s no solid evidence for that, no clinical evidence so far,” said Dr. He, associate professor of ophthalmology and director of the Retina Fellowship Program. “This study is going to try to resolve that.”

About 4,000 people between the ages of 50 and 85 with AMD in both eyes or advanced AMD in one eye, will be assessed at nearly 100 institutions over the next five years.

Age-related macular degeneration, or AMD, is the leading cause of vision loss in the United States for people over age 60. Nearly 2 million Americans have lost vision due to advanced AMD and another 7 million are at risk for losing vision.

A
'"/>




Page: 1 2

Related medicine news :

1. Nationwide Increase In Lawn Mowing Injuries
2. Nationwide Strike on May 2nd by Medicos on Reservation Issue
3. Disappointed Students Plan To Intensify Agitation Nationwide
4. Tomato Sauce reduces Cancer Risk- Study
5. Study on obesity and heart failure
6. National Lung Study in the process
7. Study casts doubt on keyboard ills
8. Study reveals how stress can make you sick
9. Study reveals how stress can make you sick
10. Study supports vegetable diet
11. Study to look at early surgery to treat epilepsy
Post Your Comments:
Breaking Medicine News(10 mins):Health News:Mike Lucas of GE Healthcare Recognized as the Lifeline for Minority Businesses; Receives the MMBDC 2009 President's Award 2Health News:The Kenneth Rainin Foundation Awards $457,000 in Grants to Support Dance, Theater, Film and Early Literacy in the San Francisco Bay Area 2Health News:The Kenneth Rainin Foundation Awards $457,000 in Grants to Support Dance, Theater, Film and Early Literacy in the San Francisco Bay Area 3Health News:Webmedx Announces #1 Ranking in KLAS 2009 Transcription Services Report 2Health News:Webmedx Announces #1 Ranking in KLAS 2009 Transcription Services Report 3Health News:Astronaut Balancing Act: Training to Help Explorers Adapt to a Return to Gravity 2Health News:Astronaut Balancing Act: Training to Help Explorers Adapt to a Return to Gravity 3Health News:Astronaut Balancing Act: Training to Help Explorers Adapt to a Return to Gravity 4Health News:Nerve-cell transplants help brain-damaged rats fully recover lost ability to learn 2Health News:Nerve-cell transplants help brain-damaged rats fully recover lost ability to learn 3
Breaking Medicine Technology:TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease 2TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease 3Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 2Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 3Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 4Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 5Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 6Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 7Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 8Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 9Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 10Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 11Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 12Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 13Roper Industries Completes the Acquisition of Verathon, Inc. 2Roper Industries Completes the Acquisition of Verathon, Inc. 3delSECUR CORPORATION Announces Agreement to Purchase the Intellectual Property Assets of the Corporation 9666 1delSECUR CORPORATION Announces Agreement to Purchase the Intellectual Property Assets of the Corporation 9666 2Advances in lung cancer research announced at conference 55064 1Advances in lung cancer research announced at conference 55064 2Fecal DNA methylation detects gastric and colorectal cancers 55060 1Fecal DNA methylation detects gastric and colorectal cancers 55060 2
Other Medicine Technology:Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 2Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 3Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 4Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 5Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 6Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 2Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 3Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 4